PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Bremelanotide, Vyleesi
🎨Melanocortin AgonistCentral melanocortin pathway. Activates MC4R in the CNS to stimulate sexual desire through brain pathways rather than vascular effects.
Kingsberg et al. (Obstet. & Gynecol.): Two identical Phase 3 RECONNECT trials showing bremelanotide significantly improves sexual desire and reduces distress in premenopausal women with HSDD.
very strongClayton et al.: Phase 3 data confirming statistically significant improvements in desire metrics with favorable safety profile (nausea, flushing, headache). Led to FDA approval.
very strongDiamond et al.: Double-blind, placebo-controlled study showing PT-141 induces significant erectile response at >7mg doses, effective even in PDE5 inhibitor non-responders.
strongComprehensive review of bremelanotide's MC4R mechanism, pharmacokinetics, clinical trial efficacy, and safety data across male and female sexual dysfunction studies.
strongNausea/hypertension possible. FDA-approved (Vyleesi) for HSDD in premenopausal women. Limited to 8 doses/month.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
FDA-approved dose: 1.75mg SubQ as needed. Max 1 dose per 24h, 8 doses/month.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
Libido enhancement typically onset within 45 minutes of dosing
Weeks 2-4
Consistent improvement in sexual response and desire
Month 2-3
Psychological effects may plateau; effectiveness maintained with intermittent use
Long-term
FDA-approved for long-term use; limit to 8 doses/month
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea From Phase 3 RECONNECT trial data | ~40% of users | moderate |
Flushing | ~20% of users | mild |
Headache | ~10% of users | mild |
Transient blood pressure increase Avoid if uncontrolled hypertension | ~8% of users | moderate |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Weekly Peptide Research
New studies · vendor alerts · protocol tips
No spam. Unsubscribe anytime. Research use only.